AAIT Treatment for Pediatric Cancers
Some children with various cancers cannot be helped with regimens of chemotherapy, radiotherapy and surgery. Development of resistance to chemotherapy, and relapsed malignancy is a leading cause of mortality in pediatrics. AAIT turns on the normal immune response to attack cancer cells via targeted NK cell activation an important advancement to cancer immunotherapy. AAIT application improves the novel humoral and cellular immune response against cancer that may greatly help children and adolescents with various malignancies. Various clinical trials of immunotherapy for pediatric cancer have recently been initiated. To date, most immune-based therapies have been well tolerated and some have shown clinically significant activity against specific refractory high-risk malignancies. Recent clinical trial results provide proof-of-principle that cancer immunotherapy has the capacity to overcome chemotherapy resistance without the usual toxicities associated with cytotoxic regimens. Envita's AAIT which is a next generation treatment in Natural Killer Cell immunotherapy holds promise for children and adolescents with various cancer types and has the potential to improve both survival and quality of life.